Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006068 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
A Phase 3 study of Ulcerative Colitis (UC), sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 950
- Enrollment target
- 20
- Study locations
NCT03006068: Active Phase 3 study of Ulcerative Colitis (UC), sponsored by AbbVie.
NCT03006068 is a Phase 3 study of Ulcerative Colitis (UC) that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 950 participants, above the 709-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03006068, a Phase 3 study of Ulcerative Colitis (UC), is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 950 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have successfully completed Study M14-234 Substudy 3.
Primary Outcome
Treatment-emergent adverse events are defined as events that begin or worsen either on or after the first dose of the study drug and within 30 days after the last dose of the study drug in the analysis period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Upadacitinib (ABT-494)
Study Locations (20)
California
- Citrus Valley Gastroenterology /ID# 151915 - Covina
- Newport Huntington Medical Group /ID# 217006 - Huntington Beach
- UC San Diego Health System /ID# 155187 - La Jolla
- United Medical Doctors /ID# 207467 - Los Alamitos
- TLC Clinical Research Inc /ID# 216830 - Los Angeles
- Gastrointestinal Biosciences Clinical Trials, LLC /ID# 157082 - Los Angeles
- Facey Medical Foundation /ID# 203135 - Mission Hills
- United Medical Doctors - Murrieta /ID# 151213 - Murrieta
- Ventura County Gastroenterology Medical Group /ID# 163417 - Oxnard
- Inland Empire Clinical Trials, LLC /ID# 216163 - Rialto
- San Diego Clinical Trials /ID# 212121 - San Diego
- Medical Assoc Research Grp /ID# 169149 - San Diego
- Univ of California San Francis /ID# 164583 - San Francisco
Arizona
- Delsol Research Management, Ll /Id# 170130 - Chandler
- Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211886 - Mesa
- Duplicate_Arizona Arthritis & Rheumatology Research, PLLC /ID# 169823 - Sun City
- Adobe Clinical Research LLC /ID# 155249 - Tucson
- Duplicate_University of Arizona /ID# 150568 - Tucson
Alabama
- East View Medical Research, LLC /ID# 171184 - Mobile
- CB Flock Research Corporation /ID# 165986 - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 950 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
What the registry record for NCT03006068 still lists
NCT03006068 is an interventional study that assigns participants to a tested intervention. The registered 950 participants enrollment target is mid-sized for trials with a published cap, above the 709-participant average among 17 other Ulcerative Colitis (UC) trials with a reported enrollment target (34% higher).
The record links to 1 condition, with Ulcerative Colitis (UC) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03006068 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT03006068 about?
NCT03006068 is a clinical study titled "A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)". This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substu...
What is the current status of trial NCT03006068?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 950 participants. The study started on 2017-01-31. Estimated completion is 2027-07.
What conditions does trial NCT03006068 study?
This clinical trial studies the following conditions: Ulcerative Colitis (UC).
What interventions are being tested in trial NCT03006068?
The interventions under investigation include: Placebo (DRUG), Upadacitinib (ABT-494) (DRUG).
Who is sponsoring clinical trial NCT03006068?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03006068 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis (UC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03006068's enrollment target sits among peer trials
950 4th of 17 higher than 14 of 17 other Ulcerative Colitis (UC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis (UC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
COMPLETED · Phase 3
-
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RECRUITING
-
Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies
RECRUITING · Phase 2
-
Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants
RECRUITING · Phase 1
-
STOP-UC: De-escalation of Therapy in Patients With Ulcerative Colitis With Histological Remission
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT04375033 · 952 participants · Phase 4
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI